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Objective: Human norovirus (HuNoV) and Clostridium difficile are common causes of infec-
tious gastroenteritis in adults in the US. However, limited information is available regarding 
HuNoV and C. difficile coinfections. Our study was designed to evaluate the prevalence of 
HuNoV and C. difficile coinfections among adult patients in a hospital setting and disease 
symptomatology.
Study design and setting: For a cross-sectional analysis, 384 fecal samples were tested for 
the presence of C. difficile toxins from patients (n=290), whom the provider suspected of C. 
difficile infections. Subsequent testing was then performed for HuNoV genogroups I and II. 
Multinomial logistic regression was performed to determine symptoms more frequently associ-
ated with coinfections.
Results: The final cohort consisted of the following outcome groups: C. difficile (n=196), C. 
difficile + HuNoV coinfection (n=40), HuNoV only (n=12), and neither (n=136). Coinfected 
patients were more likely to develop nausea, gas, and abdominal pain and were more likely to 
seek treatment in the winter season compared with individuals not infected or infected with 
either pathogen alone.
Conclusion: Our study revealed that patients with coinfection are more likely to experience 
certain gastrointestinal symptoms, in particular abdominal pain, suggesting an increased severity 
of disease symptomatology in coinfected patients.
Keywords: human norovirus, C. difficile, gastroenteritis, coinfection
What is new?
●	 The key findings are that 1) human norovirus (HuNoV) and Clostridium difficile 
coinfections are relatively frequent, 2) coinfected patients are more likely to develop 
nausea, gas, and abdominal pain, and 3) they are more likely to reside in a com-
munal setting than those not infected.
●	 The increased number of follow-up visits associated with HuNoV and C. difficile 
coinfections suggests an increased severity of gastrointestinal disease symptom-
atology in coinfected patients.
●	 A greater awareness of the high frequency of HuNoV/C. difficile coinfections, 
particularly in communal settings, may improve patient management and infection 
control.
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Acute gastroenteritis (AGE), defined as diarrheal disease of 
rapid onset potentially accompanied by nausea, vomiting, 
fever, or abdominal pain, is a major cause of illness in the 
US resulting in ~179 million episodes of AGE each year.1 
Human norovirus (HuNoV) is the leading cause of AGE 
outbreaks in the US.1 In addition, AGE is also an important 
cause of mortality worldwide, especially in children.2 In the 
US, the number of people, mostly elderly, who have suffered 
a gastroenteritis-related death has doubled during the last 
decade with Clostridium difficile representing the main and 
HuNoV the second leading infectious causes.3
C. difficile is a Gram-positive, spore-forming, and toxin-
producing bacterium. It is the most common cause of health 
care-associated infectious gastroenteritis in the US, causing 
~3 million infections yearly that result in a significant burden 
of diarrhea and colitis per year.4 Over the past decade, the 
incidence and severity of C. difficile infections (CDIs) has 
been increasing.5 C. difficile invades the disrupted intestinal 
microbiota following antibiotic treatment, and pathogenesis 
is mainly attributed to the two predominant toxins, TcdA and 
TcdB. Treatment of CDI includes antibiotic discontinuation, 
administration of specific antibiotics, such as metronidazole 
or vancomycin, or in severe cases, fecal transplants.5 How-
ever, colonization does not always result in active infection 
and a proportion of those exposed become asymptomatic 
carriers.
HuNoVs are nonenveloped, single-stranded, positive-
sense ribonucleic acid (RNA) viruses that cause ~20% of 
all cases of AGE worldwide.6 In the US alone, these viruses 
cause ~21 million infections each year.7 Approximately 5.5 
million cases, over half (58%) of all food-borne infections 
are caused by HuNoVs,8 which cost an estimated ~US$ 
5.8 billion.9 Noroviruses are divided into at least seven 
genogroups (G), three of which infect humans (GI, GII, and 
GIV).10 Genogroup II genotype 4 (GII.4) noroviruses are 
the most prevalent and clinically significant HuNoVs, caus-
ing approximately two-thirds of all outbreaks.11 Although, 
GII.17 strains are emerging and increasing in prevalence.12 
HuNoV symptoms include vomiting and diarrhea, which are 
rapid in onset but usually resolve in 12–60 hours.13 Virions 
are expelled in vomitus and/or feces of symptomatic and 
asymptomatic carriers for transmission by the fecal-oral 
route.14 There are currently no specific treatments approved 
for HuNoV infections aside from supportive care.15
Despite their health importance, little is known about 
the association between C. difficile and HuNoVs in the 
host. Although coinfections with both pathogens have been 
reported, the cohorts were very limited in number.16–18 Both 
pathogens have been mistaken as an infectious cause for 
the other19 because these pathogens share similar symptoms 
(primarily diarrhea, nausea, abdominal pain, and fever). One 
study postulated an antagonistic relationship between the 
two pathogens, in that the pathogens compete against one 
another and limit the other’s pathogenicity.17 However, the 
risk factors and clinical features associated with coinfections 
are not well understood. Therefore, the aim of our study was 
to assess the prevalence of coinfection in a cohort of patients 
with gastroenteritis, and to examine the symptomatology 
and characteristics of those coinfected with C. difficile and 
HuNoV. Findings reported herein may help with the clinical 
management of patients with gastrointestinal symptoms, as 
well as infection control and prevention.
Methods
Study population
The study population has been previously described.20 A 
cross-sectional study was conducted at the University of 
Michigan Health System (UMHS, Ann Arbor, MI, USA), 
following approval by the Institutional Review Board at the 
University of Michigan. Symptoms were determined from 
individual retrospective patient data questionnaires and 
electronic patient records from UMHS at any time prior to 
diagnosis of CDI and written informed consent was received 
from all patients from October 2010 to August 2013. All 
subjects were adults (18 years and older), who had been 
admitted for treatment at UMHS and the provider suspected 
CDI. CDI testing is ordered for symptomatic patients; for 
example, those with antibiotic-associated diarrhea. For the 
purpose of this analysis, individuals who were discharged and 
sought treatment again at least 2 weeks after the initial treat-
ment and hospital discharge were considered reinfected and 
analyzed separately. For individuals with multiple C. difficile 
test samples, the first test result and sample was used in this 
study. Controls were patients who tested negative for CDI.
Stool collection and handling
Stools samples from hospitalized inpatients and ambulatory 
outpatients presenting to the main hospital or UMHS off-
site facilities were obtained, stored in Cary-Blair transport 
media and tested for C. difficile as described.20 Specifically, 
clinician-ordered stool specimens were tested for the presence 
of C. difficile glutamate dehydrogenase antigen and toxins A 
and B using the C. DIFFICILE QUIK CHEK COMPLETE 
test (Techlab, Inc., Blacksburg, VA, USA). All antigen/toxin 
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discordant stool tests were subjected to analysis for the tcdB 
gene by real-time polymerase chain reaction (PCR) (BD 
GeneOhm™ Cdiff Assay; Franklin Lakes, NJ, USA). C. 
difficile presence was confirmed by growth on taurocholate-
cycloserine cefoxitin fructose agar plates and brain heart 
infusion-supplemented tubes at 37°C as described.21 Remain-
ing stool samples were aliquoted and stored at −80°C.
HuNoV testing
To test for the presence of HuNoV, viral RNA was extracted 
from stool samples using the QIAamp Viral RNA Mini 
Kit (Qiagen, Redwood City, CA, USA) according to the 
manufacturer’s protocol. RNA was further cleaned up with 
the TURBO DNA-free Ambion RNA kit (Thermo Fisher 
Scientific, Waltham, MA, USA) following the manufacturer’s 
recommendations.
Samples were first screened for GII HuNoV by TaqMan 
quantitative reverse transcription-PCR using CFX96 Real 
Time System (Thermo Fisher Scientific). Oligonucleotide 
primers and probe specific for the junction between ORF1 and 
ORF2 of the HuNoV genome were previously described.22 
A 20 µL PCR reaction was performed using iScript one-
step quantitative reverse transcription-PCR kit (Bio-Rad 
Laboratories Inc., Hercules, CA, USA) with the following 
conditions: 50°C (10 minutes), 95°C (5 minutes); 40 cycles at 
94°C (10 seconds) and at 60°C (30 seconds). Standard curves 
were generated from ten-fold dilutions of plasmid pSC-
GII in each run. The pSC-GII plasmid was constructed by 
amplifying 93 nt from the ORF1/2 junction of GII.4 HuNoV 
MD145-12 (nt 5007 to 5099, accession number AY032605, 
a kind gift from K. Green, National Institutes of Health) 
using the forward primer: AGCCAATGTTCAGATGGATG 
and reverse primer: TCGACGCCATCTTCATTCAC. The 
segment was cloned into vector pSC-A-amp/kan using the 
StrataClone PCR cloning system according to the manufac-
turer’s recommendations. A HuNoV-positive stool sample and 
sterile water were used in each run as positive and negative 
controls, respectively.
HuNoV samples were sequenced retrospectively after 
several years of storage and at least two freeze/thaw cycles. 
Samples were first analyzed by real-time PCR22 and RT-nested 
PCR in the RNA-dependent RNA polymerase gene and the 
junction of the 3′ end of ORF1 and 5′ end of the ORF2 was 
used (region A and region B/C according to Vinje et al23). 
Sample processing, amplification, and sequencing were 
then performed as described previously.24,25 Amplicons of 
both gene regions were added to the sequencing reactions 
using the amplification primers, the BigDye terminator v3.1 
cycle sequencing kit, and an ABI 3130xI Genetic Analyzer 
(Applied Biosystems). Sequences were aligned to prototype 
sequences drawn from GenBank and phylogenetic analysis 
was performed using BioEdit (Version 7.2.5),26 including 
CLUSTAL W (Version 1.81)27 and the PHYLogeny Inference 
Package (Version 3.6).28
Determining a detection cutoff for 
HuNoV-positive samples
Following quantitative PCR for HuNoV, all cycle threshold 
(CT) values were graphed. Similar to the study by Trang et 
al,29 we observed a biphasic distribution (data not shown). CT 
values in one group ranged from 25 to 34, while those in the 
second group ranged from 35 to 38. To decrease the potential 
of false positives, a CT value of 34 was chosen as a cutoff for 
HuNoV detection. Thus in this study, samples with CT values 
≤34 were considered HuNoV positive, while samples with a 
CT value >34 were considered HuNoV negative.
Clinical epidemiology
Symptomatology, epidemiologic, and laboratory factors were 
analyzed to determine if certain variables were predictive of 
coinfection in comparison to infection with one pathogen. 
Epidemiologic factors included patient age, sex, race, weight, 
residence when sampled, and season of diagnosis as well as 
number of follow-up visits, use of a feeding tube, antibiotic 
usage within the past 7 days, and history of chronic conditions 
(defined as history of either cardiac disease, lung disease, 
kidney disease, diabetes, autoimmune disease, inflammatory 
bowel disease, and/or acquired immunodeficiency syndrome/
human immunodeficiency syndrome). Symptomatic factors 
included vomiting, nausea, abdominal pain, urgency, and gas.
Data analysis
For statistical analysis, stool samples were categorized as 
coinfection, HuNoV only, C. difficile only, or neither based 
on laboratory results. A data set of 384 stool samples from 
290 patients was used for unadjusted and adjusted analysis. 
Statistical analyses were performed using SAS/STAT soft-
ware, Version 9.3 of the SAS System for Windows (SAS 
Institute Inc., Cary, NC, USA) and Stata MP 14.0 (StataCorp 
LP, College Station, TX, USA). A two-tailed P-value of <0.05 
was considered to be significant. The patient characteristics 
of age, sex, race, weight, residence, and previous conditions 
were noted at the time of study entry. Pearson’s chi-squared 
test was used for categorical variables and one-way analysis 
of variance for continuous variables. For antibiotic use in 
the past 7 days, use of feeding tube, and season (December 





through February vs other months) when sample was sub-
mitted, a multinomial logistic regression model was used to 
evaluate the association with infection outcomes, accounting 
for the clustering within individuals. Likewise, multinomial 
logistic regression (clustered by patient) was used to calculate 
odds ratios (ORs) and P-values for the association between 
symptoms and infection outcomes (ie, coinfection, norovirus 
only, C. difficile only, or neither infection) with adjustment 
for patient characteristics. Neither infection was used as the 
reference category. All ORs were adjusted for age, sex, and 
repeated sample collection after 2 weeks.
Results
HuNoV screening of study cohort
To determine the level of coinfection between C. difficile 
and HuNoV, we screened 384 stool samples from 290 
UMHS patients for the presence of HuNoV. The age (mean 
± standard deviation) of all patients at the time of study 
entry was 56.2 years (±16.4 years) and 44% were male. 
Of the 384 stool samples collected, 236 samples were 
positive for C. difficile, while 148 samples tested negative 
for C. difficile. Of the positive C. difficile samples, 40 also 
tested positive for HuNoV (17%). Of the 148 negative C. 
difficile samples, 12 tested positive for HuNoV (8%). A 
total of ten HuNoV samples were successfully sequenced. 
Genotyping of nine samples indicated GII.P4/GII.4 2009 
HuNoV strains, while one sample contained GII.Pg/GII.1 
HuNoV. Fecal samples from 125 patients tested negative for 
either pathogen and were used as controls. Taken together, 
the final cohort had the following outcome groups: C. dif-
ficile only (n=196 specimens, 131 patients), C. difficile + 
HuNoV (n=40 specimens, 24 patients), HuNoV only (n=12 
specimens, ten patients), and neither (n=136 specimens, 
125 patients).
Age, sex, race, and weight were similar across the four 
outcome groups at the time of enrollment (Table 1). However, 
there was a difference in infection depending upon where the 
patient resided (P=0.0004). For those with a coinfection, 21% 
lived in a rehabilitation center, nursing home, assisted living 
center, or dormitory, while only 3% of the controls lived in 
such residences. When included in a multinomial logit model 
(accounting for clustering), the difference between coinfec-
tion (specifically) and controls was significant for residential 
living (P<0.001). There was also a significant difference in 
residences for those with C. difficile and controls (P=0.014); 
11% of those with C. difficile resided in communal residences 
compared with 3% of the controls. In addition, no significant 
difference was observed in infections in the winter season 
(P=0.090) across all groups. However, a direct comparison 
of coinfection versus control (47% of coinfections occurred 
in the winter compared with 26% for controls) within a mul-
tinomial logit model demonstrated significance (P=0.017). 
Analysis of recent antibiotic use indicated no difference 
across all four outcome groups combined; although when 
patients with C. difficile were directly compared with controls 
in the multinomial logit model, the difference was significant 
(P=0.015).
Clinical symptoms of vomiting (P=0.013), nausea 
(P=0.002), and abdominal pain (P=0.012) showed sig-
nificant difference among outcomes, while no differences 
were observed for the symptoms of gastrointestinal urgency 
(P=0.920) or gas (P=0.650) (Table 2). Nausea and vomiting 
were particularly present in patients with HuNoV (75%) 
(Figure 1). Vomiting symptoms were typically combined with 
nausea and few to no patients presented with vomiting only 
(Figure 1). Furthermore, abdominal pain was the symptom 
that best differentiated those patients with a coinfection as 
abdominal pain occurred in 70% of those with a coinfec-
tion compared with 57% in controls (P=0.002) (Table 2). 
No significant difference in abdominal pain was observed 
between patients with C. difficile-only infections and hos-
pitalized controls.
To identify clinical symptoms and characteristics that 
differentiated coinfected patients from the other outcome 
Table 1 Characteristics of patients by infection status
Characteristics Coinfection Norovirus Clostridium 
difficile
Neither
Age, mean (SD) 60.2 (16.1) 58.4 (11.8) 54.8 (18.3) 56.7 (14.6)
Female, n (%) 14 (58) 5 (50) 68 (52) 74 (59)
Race (White), 
n (%)
22 (96) 7 (78) 114 (91) 110 (91)
Weight (lb), 
mean (SD)
Female 149 (50) 174 (68) 164 (53) 168 (65)
Male 181 (55) 226 (27) 183 (54) 199 (53)
Residence, n (%)
Single family 19 (79) 9 (90) 116 (89) 121 (97)
Multiplea 5 (21) 1 (10) 14 (11) 4 (3)
Previous 
conditionsb, n (%)
18 (75) 7 (70) 73 (56) 87 (70)
Winterc, n (%) 19 (47) 4 (33) 56 (29) 36 (26)
Feeding tube, 
n (%)
9 (22) 1 (8) 37 (19) 29 (21)
Antibiotics in 
past 7 days, n (%)
33 (82) 10 (83) 176 (90) 109 (0)
Notes: aRehabilitation center (n=10), assisted living center (n=9), nursing home 
(n=3), dormitory (n=1), other (n=1). bHeart disease, lung disease, kidney disease, 
diabetes, autoimmune disease, inflammatory bowel disease, and/or AIDS/HIV. 
cSample collected in December through February.
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groups with adjustment for demographic characteristics, 
repeated sampling (after 2 weeks post original sample), and 
using a quantitative PCR CT cutoff of 34 for HuNoV, there 
was a significant interaction between nausea and vomiting 
and infection status (Table 3). Coinfection was more likely in 
patients who presented with abdominal pain (OR =4.77, 95% 
confidence interval [CI]: 2.09–10.9]), nausea (OR =4.30, 
95% CI: 1.65–11.3), gas (OR =2.30, 95% CI: 1.03–5.10), or 
had a diagnosis during the winter season (December–Febru-
ary) (OR =2.30, 95% CI: 1.0–4.82). Patients with C. difficile-
only infection also had significant nausea and abdominal 
pain (OR =1.94, 95% CI: 1.04–3.60 and OR =1.70, 95% 
CI: 1.06–2.73, respectively). The ORs were greater in coin-
fected patients compared with C. difficile-only infection 
suggesting a greater prevalence of nausea and abdominal 
pain in the coinfected group. When coinfection was directly 
compared with C. difficile only, abdominal pain remained 
more prevalent in those with coinfection (OR =2.10, 95% 
CI: 1.11–3.98, P=0.023). In addition, follow-up visits were 
greater in coinfection versus C. difficile only (P=0.042). 
Those with HuNoV-only infections  were significantly 
more likely to experience vomiting (OR =5.47, 95% CI: 
0.85–34.8) compared with coinfected and C. difficile-only 
infected patients, who showed no significant association for 
vomiting as a symptom (OR =1.02, 95% CI: 0.40–2.63 and 
OR =1.21, 95% CI: 0.63–2.35, respectively). As expected, 
patients with C. difficile-only infection showed a 2.89 greater 
odds (95% CI: 1.47–5.69) of having used antibiotics in the 
7 days prior to sampling (P=0.002). Taken together, these 
data indicate that coinfected patients were more likely to 
develop nausea, gas, and abdominal pain, and were more 
likely to seek treatment in the winter season compared with 
those infected with either pathogen alone.













Yes 16 (40) 9 (75) 74 (38) 38 (28)
No 24 (60) 3 (25) 122 (62) 98 (72)
Nausea (%)
Yes 27 (68) 10 (83) 109 (44) 57 (42)
No 13 (32) 2 (17) 87 (56) 79 (58)
Abdominal 
pain (%)
Yes 28 (70) 8 (67) 104 (53) 77 (57)
No 12 (30) 4 (33) 92 (47) 59 (43)
Gastrointestinal 
urgency (%)
Yes 24 (62) 7 (58) 112 (57) 82 (61)
No 15 (38) 5 (42) 84 (43) 53 (39)
Gas (%)
Yes 26 (65) 6 (50) 117(60) 76 (56)














Figure 1 Differences in nausea and vomiting by type of infection.
Note: The percentage of patients in each outcome group was graphed according to 
symptoms: vomiting only, nausea only, neither, or both.
Table 3 Adjusted ORs for disease outcome using multinomial logistic regressiona
Disease outcome Coinfection Norovirus only Clostridium difficile only 
OR 95% CI P-value OR 95% CI P-value OR 95% CI P-value
Vomiting 1.02 0.40–2.63 0.96 5.47 0.85–34.8 0.07 1.21 0.63–2.35 0.56
Nausea 4.33 1.65–11.3 0.003 3.30 0.39–28.1 0.27 1.94 1.04–3.60 0.04
Vomiting/nauseab 0.008 <0.001 0.004
Abdominal pain 4.77 2.09–10.9 <0.001 0.77 0.21–2.88 0.70 1.70 1.06–2.73 0.03
Urgency 1.53 0.70–1.83 0.29 1.21 0.34–4.24 0.77 1.14 0.71–1.83 0.59
Gas 2.30 1.03–5.10 0.04 1.03 0.30–3.58 0.96 1.55 0.97–2.49 0.07
Winter season diagnosis 2.30 1.0–4.82 0.03 1.29 0.36–4.60 0.69 1.07 0.65–1.77 0.78
Chronic condition history 1.34 0.41–4.35 0.62 0.78 0.15–4.1 0.76 0.90 0.48–1.67 0.73
Follow-up visit number 1.71 0.78–3.73 0.18 1.63 0.49–5.44 0.42 1.81 0.96–3.40 0.07
Use of feeding tube 1.08 0.46–2.57 0.86 0.33 0.041–2.70 0.30 0.85 0.49–1.48 0.56
Antibiotic use in past 7 days 2.07 0.70–6.16 0.19 1.44 0.29–7.29 0.66 2.89 1.47–5.69 0.002
Notes: aIndividuals without norovirus or C. difficile infection constituted the reference category. All ORs were adjusted for age, sex, and repeated sample collection after 2 
weeks. bThe interaction term for nausea and vomiting. A P-value of <0.05 was considered significant.
Abbreviations: CI, confidence interval; OR, odds ratio.






The aim of this study was to determine the prevalence of C. 
difficile and HuNoV coinfection in order to aid in clinical 
diagnosis, patient management, and infection control in 
the future. Our comprehensive analysis of coinfection 
with HuNoV and C. difficile in adult hospitalized patients 
indicated that coinfections with these two pathogens occur 
relatively frequently in this patient population. Our findings 
further indicate that patients with CDI experiencing nausea 
with or without vomiting, abdominal pain, and/or gas have a 
greater likelihood of being coinfected with HuNoV, especially 
during the winter season.
Several main conclusions can be drawn from the data 
presented in this study. First, our study confirmed findings 
from previous studies regarding the occurrence of coinfec-
tions of C. difficile and HuNoV. Previous studies in a pedi-
atric population reported coinfection rates that ranged from 
13% to 17%,16,18 while 13% coinfection rates were reported 
in hospital-acquired CDI,30 and 16% in a long-term care 
facility.17 Using a next-generation sequencing approach, an 
18% coinfection rate (4/22) was detected.31 The prevalence 
of coinfection in our cohort of 384 samples was 10%. These 
slightly higher rates in previous studies may be due to a vari-
ety of reasons, such as smaller sample sizes, children being 
more likely to have asymptomatic C. difficile colonization 
in the intestinal tract,5 increased person-to-person transmis-
sion within long-term care facilities due to close proximity, 
or because we included a threshold for HuNoV positivity 
in our study.
The overall finding of coinfection raises the question 
regarding changes in disease severity in C. difficile- or 
HuNoV-infected patients compared with those coinfected 
with both pathogens. The second finding from our study 
was that patients with coinfection showed the highest mean 
number of follow-up visits compared with the other groups, 
consistent with the idea that concurrent pathogen infection 
may cause more severe disease outcomes than infection 
by either pathogen alone. Therefore, data presented herein 
indicate that the two pathogens may work synergistically 
when infecting concurrently to yield an intensified clinical 
impact in the host.
Third, our data demonstrated that the symptomatology of 
coinfections is not necessarily a combination of symptoms 
experienced with infection by a single pathogen. Vomiting 
is a well-characterized symptom during HuNoV infection.32 
However, vomiting is not a feature of CDI and no association 
with vomiting was seen in C. difficile-infected patients in our 
study. Interestingly, no association between vomiting and 
coinfection was observed. Instead, coinfection of C. difficile 
and HuNoV was associated with nausea, abdominal pain, 
and gas, symptoms more frequently experienced by patients 
infected with C. difficile. These data indicate that symptoms 
caused by CDI may be dominant over HuNoV-induced symp-
toms in the setting of coinfection. Thus, in clinical settings, it 
may be beneficial (eg, for infection control or patient manage-
ment) to take into account that patients who are diagnosed 
with CDI and present the symptoms of abdominal pain, gas, 
and nausea with or without vomiting may also be coinfected 
with HuNoV. This would be particularly important during 
the winter season because our findings also suggest that the 
season of diagnosis can impact the likelihood of coinfection 
in patients as the incidence of coinfection was significantly 
higher during the winter months. HuNoV infections often 
peak in the winter months in the Northern Hemisphere.33,34 
In contrast, CDI does not show seasonality trends because 
CDI rates are largely a result of antibiotics use.5 Therefore, 
the overall greater prevalence of HuNoV in the population 
during the winter months likely resulted in the greater odds 
of coinfection during winter that we observed in this study.
The current study also has certain limitations. One was 
the use of storage buffer for fecal samples. Transport of stool 
samples containing enteric bacterial pathogens often uses 
Cary Blair media (pH >8),35 and it was used in our study. 
However, HuNoVs are inactivated by alkaline pH.36 At pH 8, 
increased solvent exposure of tyrosine residues and second-
ary structure changes were observed, resulting in reversible 
dissociation of the viral capsid. Thus, the pH of the Cary 
Blair buffer was not optimal for viral transport/storage and 
may have resulted in degradation of viral particles over time 
and a loss of HuNoV titers in the sample. This most likely 
explains our low sequencing success rate since samples were 
sequenced several years after collection and repeated freeze/
thaw events. Therefore, it is also unlikely that the HuNoV 
genome titers measured reflect accurately the viral titers at 
the time of collection. Furthermore, the inadequate storage 
buffer may have resulted in an underreporting of HuNoV 
infections, particularly since we utilized a threshold for 
HuNoV titers to prevent false-positive classification. There-
fore, for any future studies of viral and bacterial coinfection, 
fresh, unmodified samples should be collected. Alternatively, 
parallel stool aliquots may be collected in viral as well as 
bacterial transport media.
Though our study design has limitations, the results 
may provide important guidelines for clinical practice 
and infection prevention. The identification of HuNoV in 
patients originally diagnosed to only have CDI is crucial 
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in the clinical setting due to the highly contagious nature 
of the virus, where as little as 18 HuNoV particles were 
estimated to be sufficient to cause an infection.37 Addi-
tionally, HuNoV shedding for weeks to months after the 
resolution of symptoms makes these viruses a key pathogen 
to be regulated by infection control in acute care settings.38 
In addition, while limited studies have identified HuNoV/
CDI coinfection in hospitalized and long-term care facil-
ity patients, our study serves as the first comprehensive 
analysis of coinfection with these two pathogens in adult 
hospitalized patients. This increased knowledge about the 
potential burden of coinfection in patients with gastrointes-
tinal symptoms in clinical settings may result in improved 
diagnostic procedures.
In summary, we confirmed previous studies that coin-
fections of HuNoV and C. difficile occur in adult patients 
presenting clinical symptoms of gastroenteritis. Our study 
revealed that patients with coinfection are more likely to 
experience certain gastrointestinal symptoms – abdominal 
pain, gas, and nausea with or without vomiting – and show 
increased numbers of follow-up visits, suggesting direct 
or indirect interactions between these pathogens in the 
host during infection. These findings are consistent with 
an increased severity of disease in coinfected individuals 
but future studies are needed to identify the underlying 
mechanisms of pathogen interactions within the host, or 
whether the order of pathogen acquisition dictates patient 
outcomes. Regardless, clinicians diagnosing patients with 
CDI should be aware of possible HuNoV coinfections and 
the consequences for clinical treatment and infection pre-
vention management.
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